Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 81.92% is 11% above its 5-year average of 73.69%, near the high end of its 5-year range (66.17%–81.92%).
As of the fiscal period ended Tuesday, March 31, 2026. 8.14% above its 12-month average of 75.76%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
81.92%
GROSS MARGIN AVG TTM
75.76%
GROSS MARGIN AVG 3Y
74.57%
GROSS MARGIN AVG 5Y
73.65%
GROSS MARGIN AVG 10Y
70.89%
GROSS MARGIN AVG 15Y
68.18%
GROSS MARGIN AVG 20Y
68.86%
CURRENT VS TTM AVG
+8.14%
CURRENT VS 3Y AVG
+9.86%
CURRENT VS 5Y AVG
+11.23%
CURRENT VS 10Y AVG
+15.56%
CURRENT VS 15Y AVG
+20.16%
CURRENT VS 20Y AVG
+18.97%
SECTOR MEDIAN · HEALTHCARE
58.51%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+40.02%
vs the sector median at left
Merck & Co., Inc.
Market Cap
$323.72B
Gross Margin
81.92%
TTM Avg
75.76%
3Y Avg
74.57%
5Y Avg
73.65%
Market Cap
$382.09B
Gross Margin
22.49%
TTM Avg
20.43%
3Y Avg
22.48%
5Y Avg
23.36%
Market Cap
$211.18B
Gross Margin
40.37%
TTM Avg
39.50%
3Y Avg
40.36%
5Y Avg
43.54%
Market Cap
$179.58B
Gross Margin
56.80%
TTM Avg
53.17%
3Y Avg
51.86%
5Y Avg
51.92%
Market Cap
$160.55B
Gross Margin
79.35%
TTM Avg
78.55%
3Y Avg
78.10%
5Y Avg
78.28%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $323.72B | 81.92% | 75.76% | 74.57% | 73.65% |
| UnitedHealth Group Incorporated (UNH)vs › | $382.09B | 22.49% | 20.43% | 22.48% | 23.36% |
| AstraZeneca PLC (AZN)vs › | $262.31B | 81.68% | 81.51% | 79.26% | 77.31% |
| Novo Nordisk A/S (NVO)vs › | $216.72B | 81.83% | 82.83% | 83.54% | 83.48% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $211.18B | 40.37% | 39.50% | 40.36% | 43.54% |
| Amgen Inc. (AMGN)vs › | $202.95B | 71.46% | 66.16% | 69.53% | 71.51% |
| AbbVie Inc. (ABBV)vs › | $458.11B | 70.68% | 70.11% | 68.16% | 68.00% |
| Abbott Laboratories (ABT)vs › | $179.58B | 56.80% | 53.17% | 51.86% | 51.92% |
| Gilead Sciences, Inc. (GILD)vs › | $160.55B | 79.35% | 78.55% | 78.10% | 78.28% |
| Pfizer Inc. (PFE)vs › | $139.86B | 69.35% | 68.05% | 62.23% | 63.06% |
Gross Margin
81.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 81.92% |
| 2025-12-31 | 70.49% |
| 2025-09-30 | 75.59% |
| 2025-06-30 | 75.65% |
| 2025-03-31 | 75.13% |
| 2024-12-31 | 75.50% |
| 2024-09-30 | 75.51% |
| 2024-06-30 | 76.76% |
| 2024-03-31 | 77.56% |
| 2023-12-31 | 73.26% |
| 2023-09-30 | 73.29% |
| 2023-06-30 | 73.24% |
| 2023-03-31 | 72.90% |
| 2022-12-31 | 71.94% |
| 2022-09-30 | 73.70% |
| 2022-06-30 | 71.11% |
| 2022-03-31 | 66.17% |
| 2021-12-31 | 71.35% |
| 2021-09-30 | 73.77% |
| 2021-06-30 | 72.78% |
| 2021-03-31 | 69.90% |
| 2020-12-31 | 55.79% |
| 2020-09-30 | 72.43% |
| 2020-06-30 | 70.63% |
| 2020-03-31 | 72.53% |
| 2019-12-31 | 69.08% |
| 2019-09-30 | 67.81% |
| 2019-06-30 | 71.08% |
| 2019-03-31 | 71.78% |
| 2018-12-31 | 70.09% |
| 2018-09-30 | 66.47% |
| 2018-06-30 | 67.35% |
| 2018-03-31 | 68.28% |
| 2017-12-31 | 67.35% |
| 2017-09-30 | 67.97% |
| 2017-06-30 | 68.62% |
| 2017-03-31 | 67.68% |
| 2016-12-31 | 67.06% |
| 2016-09-30 | 67.64% |
| 2016-06-30 | 63.65% |
| 2016-03-31 | 61.64% |
| 2015-12-31 | 62.31% |
| 2015-09-30 | 62.66% |
| 2015-06-30 | 61.64% |
| 2015-03-31 | 62.13% |
| 2014-12-31 | 64.23% |
| 2014-09-30 | 60.00% |
| 2014-06-30 | 55.25% |
| 2014-03-31 | 61.97% |
| 2013-12-31 | 59.30% |
| 2013-09-30 | 62.80% |
| 2013-06-30 | 61.09% |
| 2013-03-31 | 62.90% |
| 2012-12-31 | 64.56% |
| 2012-09-30 | 63.99% |
| 2012-06-30 | 66.60% |
| 2012-03-31 | 65.59% |
| 2011-12-31 | 66.03% |
| 2011-09-30 | 63.80% |
| 2011-06-30 | 64.74% |
| 2011-03-31 | 64.95% |
| 2010-12-31 | 63.29% |
| 2010-09-30 | 62.33% |
| 2010-06-30 | 59.91% |
| 2010-03-31 | 54.33% |
| 2009-12-31 | 51.44% |
| 2009-09-30 | 76.36% |
| 2009-06-30 | 77.05% |
| 2009-03-31 | 75.23% |
| 2008-12-31 | 75.63% |
| 2008-09-30 | 75.14% |
| 2008-06-30 | 76.92% |
| 2008-03-31 | 78.73% |
| 2007-12-31 | 75.26% |
| 2007-09-30 | 75.01% |
| 2007-06-30 | 74.60% |
| 2007-03-31 | 73.55% |
| 2006-12-31 | 72.38% |
| 2006-09-30 | 71.46% |
| 2006-06-30 | 74.96% |
| 2006-03-31 | 75.18% |
| 2005-12-31 | 74.35% |
| 2005-09-30 | 77.13% |
| 2005-06-30 | 78.77% |
| 2005-03-31 | 76.29% |
| 2004-12-31 | 77.67% |
| 2004-09-30 | 75.37% |
| 2004-06-30 | 80.67% |
| 2004-03-31 | 79.61% |
| 2003-12-31 | 78.17% |
| 2003-09-30 | 81.20% |
| 2003-06-30 | 82.11% |
| 2003-03-31 | 80.61% |
| 2002-12-31 | 37.49% |
| 2002-09-30 | 82.06% |
| 2002-06-30 | 35.26% |
